Berberine Sulfate Inhibits Tumor-Promoting Activity of Teleocidin in Two-Stage Carcinogenesis on Mouse Skin

Nishino, H; Kitagawa, Kouichiro; Fujiki, Hirota; Iwashima, Akio

doi:10.1159/000226349

Cited by 68 publications

(29 citation statements)

References 3 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Berberine not only induced pgp-170 expression on six cancer cell lines (Figure 1) but also elevated the function of pgp-170 in these cancer cell lines (Figure 2). Nishino et al had found that berberine inhibited the effect of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced responses (Nishino et al, 1986). In another study, the accumulation of TPA and TPA-induced protein kinase C activity in MDR-expressed KB cells are slightly less than the MDR-negative KB cells (Cloud-Heflin et al, 1996).…”

Section: Discussionmentioning

confidence: 98%

Berberine modulates expression of mdr1 gene product and the responses of digestive track cancer cells to Paclitaxel

Lin

Liu

et al. 1999

Br J Cancer

View full text Add to dashboard Cite

Berberine is the major constituent of Coptis chinese and is commonly used in Chinese herbal medicine to treat patients with gastrointestinal disorders. In this study, using flow cytometry, we have found that a 24-h berberine treatment up-regulated the multidrug-resistant transporter (pgp-170) expression in two oral (KB, OC2), two gastric (SC-M1, NUGC-3) and two colon (COLO 205, CT 26) cancer cell lines. Decreased retention of rhodamine 123 was observed in berberine-treated cells as compared to vehicle control. To examine whether the berberine modulated pgp-170 expression in cancer cells is associated with changes in drug resistance, we determined the cytotoxicity, cell cycle progression and cell morphology of Paclitaxel-treated cells. Paclitaxel (1 n M –10 μ M ) treatment for 24 h induced cytotoxicity in OC2, SC-M1 and COLO 205 cells in a dose-dependent manner. Pretreatment of cells with 32 μ M berberine for 24 h prior to Paclitaxel treatment resulted in increased viability as compared to that of Paclitaxel-treated cells. In addition, Paclitaxel-induced apoptosis and/or G2/M arrest in these three cancer cell lines. Pretreatment of cells with berberine prior to Paclitaxel blocked the Paclitaxel-induced cell cycle responses and morphological changes. These results together suggest that berberine modulated the expression and function of pgp-170 that leads to reduced response to Paclitaxel in digestive track cancer cells. © 1999 Cancer Research Campaign

show abstract

Section: Discussionmentioning

confidence: 98%

Berberine modulates expression of mdr1 gene product and the responses of digestive track cancer cells to Paclitaxel

Lin

Liu

et al. 1999

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…The potential effectiveness of berberine is indicated by its use in the Indian Ayurvedic (10), Unani, and Chinese systems of medicine since time immemorial. Berberine has been shown to possess antiinflammatory activities in vivo (11) and preliminary studies have been conducted to determine its anticarcinogenic activity in skin (12). It has been shown to inhibit activator protein 1, a key transcription factor in inflammation and carcinogenesis, in human cell lines (13) and has been shown to possess antitumor properties and effectively inhibit cyclooxygenase-2 transcriptional activity in human colon cancer cells (14,15).…”

Section: Introductionmentioning

confidence: 99%

Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells

Mantena¹,

Sharma²,

Katiyar

2006

Molecular Cancer Therapeutics

321

218

View full text Add to dashboard Cite

Berberine, a naturally occurring isoquinoline alkaloid, has been shown to possess anti-inflammatory and antitumor properties in some in vitro systems. Here, we report that in vitro treatment of androgen-insensitive (DU145 and PC-3) and androgen-sensitive (LNCaP) prostate cancer cells with berberine inhibited cell proliferation and induced cell death in a dose-dependent (10 -100 Mmol/L) and timedependent (24 -72 hours) manner. Treatment of nonneoplastic human prostate epithelial cells (PWR-1E) with berberine under identical conditions did not significantly affect their viability. The berberine-induced inhibition of proliferation of DU145, PC-3, and LNCaP cells was associated with G 1 -phase arrest, which in DU145 cells was associated with inhibition of expression of cyclins D1, D2, and E and cyclin-dependent kinase (Cdk) 2, Cdk4, and Cdk6 proteins, increased expression of the Cdk inhibitory proteins (Cip1/p21 and Kip1/p27), and enhanced binding of Cdk inhibitors to Cdk. Berberine also significantly (P < 0.05 -0.001) enhanced apoptosis of DU145 and LNCaP cells with induction of a higher ratio of Bax/Bcl-2 proteins, disruption of mitochondrial membrane potential, and activation of caspase-9, caspase-3, and poly(ADP-ribose) polymerase. Pretreatment with the pan-caspase inhibitor z-VAD-fmk partially, but significantly, blocked the berberineinduced apoptosis, as also confirmed by the comet assay analysis of DNA fragmentation, suggesting that berberineinduced apoptosis of human prostate cancer cells is mediated primarily through the caspase-dependent pathway. The effectiveness of berberine in checking the growth of androgen-insensitive, as well as androgensensitive, prostate cancer cells without affecting the growth of normal prostate epithelial cells indicates that it may be a promising candidate for prostate cancer therapy.

show abstract

“…It also exhibits antitumor, antimicrobial, and even antidiabetic effects (31)(32)(33)(34)(35)(36). Moreover, a recent report suggested that BBR may be efficacious in experimental type I diabetes (37), raising the possibility of its use as a treatment for autoimmune diseases.…”

mentioning

confidence: 99%

Regulation of Th1 and Th17 Cell Differentiation and Amelioration of Experimental Autoimmune Encephalomyelitis by Natural Product Compound Berberine

Qin

Guo

Wan

et al. 2010

The Journal of Immunology

103

View full text Add to dashboard Cite

Berberine (BBR), an isoquinoline alkaloid derived from plants, is widely used as an anti-inflammatory remedy in traditional Chinese medicine. In this study, we showed that BBR was efficacious in the amelioration of experimental autoimmune encephalomyelitis (EAE) through novel regulatory mechanisms involving pathogenic Th1 and Th17 cells. BBR inhibited differentiation of Th17 cells and, to a lesser degree, Th1 cells through direct actions on the JAK/STAT pathway, whereas it had no effect on the relative number of CD4+Foxp3+ regulatory T cells. In addition, BBR indirectly influenced Th17 and Th1 cell functions through its effect on the expression and function of costimulatory molecules and the production of IL-6, which was attributable to the inhibition of NF-κB activity in CD11b+ APCs. BBR treatment completely abolished the encephalitogenicity of MOG35–55-reactive Th17 cells in an adoptive transfer EAE model, and the same treatment significantly inhibited the ability of MOG35–55-reactive Th1 cells to induce EAE. This study provides new evidence that natural compounds, such as BBR, are of great value in the search for novel anti-inflammatory agents and therapeutic targets for autoimmune diseases.

show abstract

Berberine Sulfate Inhibits Tumor-Promoting Activity of Teleocidin in Two-Stage Carcinogenesis on Mouse Skin

Cited by 68 publications

References 3 publications

Berberine modulates expression of mdr1 gene product and the responses of digestive track cancer cells to Paclitaxel

Berberine modulates expression of mdr1 gene product and the responses of digestive track cancer cells to Paclitaxel

Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells

Regulation of Th1 and Th17 Cell Differentiation and Amelioration of Experimental Autoimmune Encephalomyelitis by Natural Product Compound Berberine

Contact Info

Product

Resources

About